We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Leads UK’s International Travel Testing Efforts in Response to New Omicron Variant

By LabMedica International staff writers
Posted on 02 Dec 2021
Image: Randox Leads UK’s International Travel Testing Efforts in Response to New Omicron Variant (Photo courtesy of Randox Laboratories)
Image: Randox Leads UK’s International Travel Testing Efforts in Response to New Omicron Variant (Photo courtesy of Randox Laboratories)

Randox Laboratories (Crumlin, UK) is leading the UK’s effort to expand PCR testing to support international travel in response to the emergence of the Omicron variant of COVID-19.

The outbreak of Omicron prompted the UK government to announce late on Saturday 27th November that it would stop accepting lateral flow tests as valid entry for international arrivals from Tuesday 30th November. The unexpected move has put pressure on the diagnostics industry to rapidly boost PCR testing efforts to ensure as little disruption as possible to international travel prior to and during the Christmas break. Randox has responded within 48 hours by returning international travel PCR capacity within its laboratories to 180,000 tests per day, with a potential to increase the number further. It has also immediately invested an additional GBP 10 million in consumable materials to enable high volume Day 2 PCR testing with next-day results.

Since the start of the pandemic, Randox has built, equipped and staffed over 80,000 square feet of PCR laboratories. In addition to its Northern Ireland facilities, it has opened further PCR laboratories in Manchester and Greater London and added 1,000 additional staff to support high volume PCR testing 24 hours a day, seven days a week, 365 days a year. Randox has processed over 21 million PCR tests to date, including more than 15 million for the UK’s National Testing Programme, and is the only laboratory in the UK to have processed over 100,000 PCR tests in a single day.

“Our 40 years of experience in testing and diagnostics have enabled us to rise to the challenges presented by this national and global crisis. We are proud to continue to provide an efficient service that represents value for money for both the National Testing Programme and the travelling public,” said a Randox spokesperson. “Having expanded our overall workforce in the face of this pandemic to over 3,300 we are well-placed to rapidly redeploy staff in response to the government’s fast decision to switch to PCR testing only for international travelers. These staff redeployments facilitate both laboratory testing and the high-volume preparation and dispatch of the critical sample collection kits that are essential to our service. We currently have a capacity for international travel of 180,000 PCR tests per day and we are confident we will be able to keep pace with demand for these essential tests.”

Related Links:
Randox Laboratories 

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
8-Channel Pipette
SAPPHIRE 20–300 µL

Channels

Molecular Diagnostics

view channel
Image: ARIA can appear as brain swelling or small hemorrhages on MRI scans and remains difficult to predict before treatment begins (Reisa A, Sperling et al, via Wikimedia Commons, CC BY 4.0)

Blood Immune 'Fingerprint' Predicts Side Effects of New Alzheimer's Drug

New antibody therapies for Alzheimer’s disease have shown promise in slowing disease progression, but their broader use has been limited by a common side effect known as amyloid-related imaging abnormalities (ARIA).... Read more

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
INTEGRA BIOSCIENCES AG